However, EGFR‐TKIs, as the first type of targeted drugs in NSCLC, are specifically targeted to driver mutations of EGFR and inhibit their prosurvival activity, an effect which lacks a direct link to DNA damage and repair. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.